[144] CYTOKINETICS INC SEC Filing

Rhea-AI Filing Summary

Insider sale notice for CytoKinetics (CYTK). An individual proposes to sell 6,757 common shares with an aggregate market value of $384,946.29, representing approximately 0.00565% of the 119,657,156 shares outstanding. The proposed approximate sale date is 10/06/2025 on NASDAQ. The shares were acquired as restricted stock units on 01/04/2021.

The filing also discloses recent automated sales under a 10b5-1 plan: 6,695 shares sold on 09/30/2025 for $368,727.79 and 6,756 shares sold on 09/02/2025 for $337,800.00. The filer certifies no undisclosed material adverse information and signals use of a trading plan or instructions consistent with Rule 10b5-1 practice.

Insights

Insider Transactions Analyst

Small, routine insider disposition via Rule 10b5-1; limited market impact.

The filing shows a proposed sale of 6,757 common shares valued at $384,946.29, following 10b5-1 sales of 6,695 and 6,756 shares in September 2025. These shares were issued as restricted stock units on 01/04/2021, indicating the transactions are dispositions of previously granted compensation.

The proposed sale equals about 0.00565% of the outstanding share count, so the transactions are unlikely to move the market by themselves. Monitor any additional filings or larger cumulative insider sales over the next 30–90 days for potential signal changes.

Corporate Governance Specialist

Use of 10b5-1 language and signature representation reduces insider-trading ambiguity.

The notice includes the 10b5-1 sales record and a signed representation that no undisclosed material adverse information is known, which aligns with standard disclosure practices for planned insider sales. The shares were acquired as RSUs, confirming these are compensation-related disposals rather than open-market purchases.

Governance watchers should note the presence of a trading plan date (implicit) and check for any subsequent Form 4 or Form 144 filings within the next reporting cycle to see if this pattern continues or if larger-scale sales occur.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6757	384946.29	119657156	10/06/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/04/2021	Restricted Stock Units	Issuer			6757	01/04/2021	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for EDWARD KAYE 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080	Common	09/30/2025	6695	368727.79
10b5-1 Sales for EDWARD KAYE 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080	Common	09/02/2025	6756	337800.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)